Opening Asia for Russia

Clinical trials of the Sputnik V vaccine have begun at MEDSI

07.10.2020 41 просмотров

MEDSI Group of Companies JSC announces the launch of clinical trials of the Sputnik V vaccine for the prevention of the new coronavirus infection SARS-CoV-2. 


batch of the vaccine produced at the Binnopharm Zelenograd plant, which is part of the pharmaceutical holding AFK Sistema, was received by "MEDSI" for post-registration tests. 

Free vaccination is carried out on the basis of the MEDSI Clinical Diagnostic Center » on Solyanka under the guidance of an infectious disease specialist, Doctor of Medical Sciences, Professor Irina Shestakova. The first group of vaccinated people includes about 500 people, and in total it is planned to attract up to 2000 volunteers. Age of volunteers - from 18 years. The total duration of the study will be 180 days. Anyone can take part in the tests if there are no contraindications to vaccination. 

The test procedure, criteria for selecting volunteers, a set of insurance and other guarantees are strictly regulated by the protocol of the Ministry of Health of the Russian Federation. To participate in the program, the patient signs an informed consent for a clinical trial of the vaccine, receives an insurance policy, and undergoes a full medical examination. In case of admission to vaccination, the program participant installs a mobile application for health monitoring. Re-vaccination is carried out after 21 days. After each vaccination, the program participant is obliged to report any changes in the state of health through a mobile application and telemedicine consultations with a specialist. private medical organizations involved in clinical trials of a vector vaccine against coronavirus infection. The vaccine was obtained in a biotechnological way, which does not use the SARS-CoV-2 virus pathogenic for humans. 

The world's first registered vaccine for the prevention of coronavirus infection was developed by the National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. . Gamaleya". A platform for the production of the Russian vaccine, in addition to the N.F. Gamaleya, is the Binnopharm pharmaceutical plant, which is part of the AFK Sistema Group. 

The Medsi Group of Companies is a leading federal network of private medical clinics that provides a full range of medical services - from primary appointments and emergency medical assistance to high-tech diagnostics, complex surgical interventions and rehabilitation. Today, MEDSI's assets include 27 clinics in Moscow and the Moscow region (including 2 children's clinics, 2 clinical hospitals and 5 clinical diagnostic centers), 18 clinics in the regions of Russia, an ambulance service, a home help service, medical wellness and 2 sanatoriums. The company's revenue in 2019 amounted to 22.3 billion rubles. About 8.5 million people visit MEDSI clinics every year.

Новости партнёров